Kuroshima, Kazuki <br/><br/>
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.  [electronic resource] 

 -  Cancer science  May 2020 
 - 1607-1618 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1349-7006 
<br/><br/><label>Standard No.: </label>10.1111/cas.14395  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Carcinoma, Renal Cell--drug therapy<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Mice<br/>Mice, Nude<br/>Protein Kinase Inhibitors--pharmacology<br/>Signal Transduction--drug effects<br/>Sirolimus--analogs & derivatives<br/>Sunitinib--pharmacology<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors